Abbreviations used are: P-gp, P-glycoprotein; C max , maximum concentration; AUC 0-24hr , area under the plasma concentration time-curve from time 0 to 24 hr; DDI, drug-drug interactions; CNS, central nervous system; SD, Sprague-Dawley; PBS, phosphate-buŠered saline; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; BCRP W bcrp, breast cancer resistance protein; MRP2 W mrp2, multidrug resistance-associated protein 2; Hank's balanced salt solution, HBSS; HEPES, 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid; MES, 2-(N-morpholino)ethanesulfonic acid. Summary: The in‰uence of P-glycoprotein (P-gp) on intestinal absorption of drugs was investigated by comparison of the uptakes of two P-gp substrates, verapamil and vinblastine, using intestinal segments of wild-type and mdr1a W 1b gene-deˆcient (mdr1a W 1b -W -) mice, and Caco-2 cells. When [ 3 H]vinblastine was injected into intestinal segments of wild-type mice, vinblastine was absorbed from duodenum and ileum, but not from jejunum. This diŠerence among intestinal regions could not be explained by segmental diŠerences of mdr1a mRNA expression. In Caco-2 cells, it was found that vinblastine had a high value of eOEux W in‰ux ratio (an index of a‹nity for P-gp) of 12.1, and a low permeability of less than 1×10 -6 cm W sec. The corresponding values for verapamil were 4.9 and 10.6×10
Introduction
The drug eOEux transporter P-glycoprotein (P-gp, mdr1, ABCB1) is expressed not only in drug-resistant tumor cells, but also in many normal tissues with excretory functions, including the bile canalicular membrane of hepatocytes, the luminal membrane of endothelial cells in the blood-brain barrier, the epithelial apical membrane of the intestine, and renal proximal tubules. Thus, P-gp may play an important role in the barrier function of these tissues against xenobiotic drugs. Studies of clinical drug-drug interactions (DDI) involving P-gp have focused mainly on central nervous system (CNS) toxicities arising from the translocation of excessive amounts of P-gp substrates to the brain. 1) Candidate drugs in development are often examined to see whether they are P-gp substrates or not, from the viewpoints of potential DDI, and drug distribution to the CNS. Moreover, DDI involving renal clearance via P-gp has been observed clinically. 2) In contrast, there have been few clinical reports of serious DDI involving intestinal absorption. Further, the absorption rates of various P-gp substrates after oral administration are good in humans. For example, the absorption rates of digitoxin, quinidine, digoxin, nifedipine, amiodarone, propranolol, cyclosporine (Sandimmun TM ) and verapamil are 90, 80, 70, 50, 46, 26, 23 and 22z, respectively, according to the manufacturers' drug informa-tion sheets. Therefore, several researchers have suggested that the in‰uence of P-gp on intestinal absorption of drugs is relatively limited. [3] [4] [5] [6] [7] However, other authors have found that P-gp substrates do show P-gp-dependent intestinal absorption. [8] [9] [10] [11] Since P-gp substrates with low absorption would not have been successfully developed as oral drugs, it can not necessarily be assumed that P-gp has little eŠect on intestinal drug absorption, based onˆndings with clinically used drugs. In this study, we investigated the eŠect of P-gp on intestinal absorption of drugs by using FVB wild-type mice (mdr1a W 1b ＋ W ＋ ), mdr1a W 1b gene-deˆcient (mdr1a W 1b -W -) mice and Sprague-Dawley (SD) rats. Verapamil, which is administered orally in clinical use, and vinblastine, which is administered intravenously, were tested as typical substrates of P-gp. Moreover, we attempted to develop a biochemical classiˆcation procedure using Caco-2 cells, to predict which P-gp substrates are likely to show P-gp-dependent intestinal absorption. and used at 7 to 14 weeks of age. Male SD rats, 6-7 weeks of age, were obtained from Japan SLC (Hamamatsu, Japan). The animals were individually housed at constant temperature (23±29 C) and humidity (55±15z), with a 12 h W 12 h light W dark cycle, and were allowed free access to water and commercial diet, CE-2 (Clea Japan Inc., Tokyo, Japan).
Methods
Absorption ratio in intestine: Five 3-cm loops of segments of the small intestine, i.e., duodenum, middle jejunum, distal jejunum, middle ileum and terminal ileum from the same FVB wild-type or mdr1aW 1b , and then 300 mL of 100 mM EDTA, and 150 mL of 30z hydrogen peroxide was added. The bleached solution was mixed with a scintillation cocktail (Atomlight TM ; NEN, Boston, MA) to measure the radioactivity. The absorption ratio was calculated from the recovered radioactivity in the intestinal loop and contents, Absorption ratio＝1-(Recovered radioactivity W Dosed radioactivity)×100 (z)
Extraction of RNA, reverse transcription, and assay of mRNA expression by real-time PCR: Mdr1a W 1b
and mdr1a W 1b -W -mice were killed, and tissues were collected and rapidly frozen until required. Duodenum, jejunum, ileum, colon, rectum and liver were identiˆed and cleaned several times in ice-cold phosphate-buŠered saline (PBS), then the mucosal cell layers were scraped oŠ on ice and rapidly frozen. The duodenum was identiˆed as proximal to the ligament of Treitz (ˆrst 2 cm), the jejunum as the upper part (upper 2 W 5) of the small intestine distal to the ligament of Treitz and the ileum as the lower part (lower 2 W 5) of the small intestine ending before the cecum. Between the duodenum and jejunum, 5 cm of tissue was removed as a safety margin, as well as 10 cm between the jejunum and ileum. The total colon was used for mucosa isolation. Total RNA was extracted from 30 mg of mucosal tissue using Sepasol RNA I TM reagent (Nacalai Tesque, Kyoto, Japan) according to the manufacturer's instructions. First-strand cDNA was synthesized using ReverTra Ace TM (Toyobo, Osaka, Japan) with an oligo(dT) primer. Real-time PCR was performed as previously described 12) according to the recommendations of Applied Biosystems (http: W W home.appliedbiosystems. com). Taqman-Primers for mdr1a, mdr1b, breast cancer resistance protein (bcrp), multidrug resistanceassociated protein 2 (mrp2), and cyp3a11 genes were purchased from Applied Biosystems (Tokyo, Japan). The passive reference dye (ROX) was included in the Taqman buŠer supplied by the manufacturer. Twenty microliters of cDNA obtained from the RT reaction was diluted to 100 mL with RNAse-free water. PCR was conducted in a 25 mL reaction volume, using 5 mL of diluted cDNA as a template, with sense and antisense primers (25 mM each) and the labeled probe (5 mM). The Taqman Universal PCR Master Mix TM (Applied Biosystems) was added to theˆnal volume. Prior quantiˆcation experiments had determined the optimal concentrations of primers and probes, and the optimum temperature settings to maximize ‰uorescence signals and PCR products. Reactions were run in 96-well optical reaction plates using a Prism 9600 cycler (Applied Biosystems). Conditions were as follows: initial 959 C (10 min) and then 40 cycles of 959 C (15 s) and 609 C (1 min) with auto ramp time. For analysing the data, the threshold was set to 0.06, as this value had been determined to be in the linear range of the ampliˆcation curves for all mRNAs in all experimental runs. All reactions were run in triplicate. The abundance of the target mRNAs was calculated relative to a reference mRNA (glyceraldehyde 3-phosphate dehydrogenase, GAPDH). Since standard curves made for all primer pairs with jejunum RNA had revealed an e‹ciency value close to 2 (fold-increase in input mRNA required to decrease the cycle number by 1), relative expression ratios were calculated as R＝2
(Ct(GAPDH)-Ct(test)) , where Ct is the cycle number at the threshold and test indicates the tested mRNA. GAPDH mRNA was measured in all samples and the values obtained were used to normalize data for test mRNAs.
Cell culture and transport experiments Caco-2: Cells were obtained from American Type Culture Collection (Rockville, MD). Polycarbonate membrane Transwell TM clusters, 11.2 mm in diameter and 3.0 mm pore size, were purchased from Corning (Acton, MA). The cultivation of Caco-2 cells was performed as described previously. 13) All cells used in this study were between passages 17 and 26. Caco-2 cells were maintained at 379 C in a humidiˆed atmosphere of 5z CO 2 in air. Cells were seeded on a 12-well Transwell at a density of 60000 cells W cm 2 . Caco-2 cells were cultured for 21 days with Dulbecco's modiˆed Eagle's medium (Sigma, St. Louis, MO) with 10z fetal bovine serum. Culture medium was replaced three times a week. The cells were used for transport experiments as described previously. 13, 14) Monolayer integrity was assessed by measuring TEERs using a Millicell electrical resistance system (Millipore Corp., Bedford, MA) and the average TEER value was 738±94 Q･cm 2 . Transport solutions of non-labeled compounds were prepared by adding 1 mM DMSO stock solutions of test compounds to transport buŠer to give theˆnal concentration at 5 mM. To initiate transport for the apical-to-basolateral study, 1.5 mL of HBSS (pH 7.4, 379 C) was introduced on the basolateral side (receiver side) and 0.5 mL of the test solution (pH 6.0, 379 C) containing radio-labeled or non radiolabeled compound was loaded on the apical side (donor side) of a cell insert. At 15, 30, 45 and 60 min after the loading, 0.5 mL aliquots of the solution were removed from the receiver side and replaced with an equal volume of fresh HBSS. In the case of eOEux evaluation (basolateral-to-apical study), to initiate transport, 1.5 mL of the test solution (pH 7.4, 379 C) containing radiolabeled or non radio-labeled substrate was loaded on the basolateral side as the donor side and 0.5 mL of MES (pH 6.0, 379 C) was introduced on the apical side as the receiver side of a cell insert. At designated times after loading, 0.1 mL aliquots of the solution were removed from the receiver side and replaced with an equal volume of fresh MES. The apparent permeability coe‹cients (Papp,in‰ux and Papp,eOEux) were calculated using the following equation:
where dQ W dt is the permeability rate, C0 is the initial concentration in the donor compartment, and A is the surface area of the membrane. The eOEux rate (dQ W dt× 1 W A) was calculated by plotting the amount transported per unit area as a function of time and determining the slope of the line using linear regression. Each result represents the mean of two experiments using the same culture of Caco-2 cells.
Pharmacokinetic study: Animals was deprived of food for 12 hrs before experiments. [ 3 H]Verapamil or [ 3 H]vinblastine was dissolved at a concentration of 1 mgW 10 mL with non-labeled compound and physiological saline, and orally administered to mice at a single dose of 1 mg W kg. In the rat study, only [ 3 H]vinblastine was administered. Blood samples were withdrawn from the orbital sinus of mice with a heparinized capillary or from the jugular vein of rats with a heparinized syringe at designated times, under anesthesia induced with diethyl ether. Blood were centrifuged (1700×g) for 15 min at 49 C to obtain plasma. The plasma sample was mixed with a scintillation cocktail (Aquasol TM ; Packard, Meriden, CT) to measure the radioactivity. The maximum plasma concentration (Cmax) and time to Cmax (Tmax) were determined directly from the observed data. The area under the plasma concentration-time curve from time 0 to 24 hr (AUC0-24hr) was estimated by the linear trapezoidal method. Each value is the mean± S.D. of three animals. Statistical analysis for Cmax and AUC0-24hr was performed with Student's two-tailed t test. The diŠerence between means was considered to be signiˆcant when the P-value was less than 0.05.
Analytical method: Radioactivity was determined with a liquid scintillation counter (LS6000TA, Beckman, Fullerton, CA). Non-labeled samples were analyzed with a NanoSpace TM HPLC system (Shiseido, Tokyo, Japan) coupled to a TSQ Quantum TM triple quadrupole mass spectrometer (Thermo Electron Corp., San Jose, CA) via an electron spray ionization interface under the conditions described below. Colchicine was separated with a Capcellpak TM DD column (150×2.0 mm i.d., Shiseido, Tokyo, Japan) using isocratic elution at 0.2 mL W min with 55z 0.1z-formic acid W 45z methanol. Positive ion selected reaction monitoring was done using the transition 400.0 to 358.0. Fexofenadine was separated with a Capcellpak TM DD column using isocratic elution with 46z 0.1z-formic acid W 54z methanol, with monitoring of the 502.2 to 466.1 transition. Cyclosporine was separated with a Capcellpak TM MGII column (150×2.0 mm i.d., Shiseido, Tokyo, Japan) using isocratic elution with 14.5z 0.1z-formic acid W 85.5z methanol; the 1219.9 to 1202.9 transition was monitored. Digoxin was separated with a Capcellpak TM MGII column using isocratic elution with 55z 20 mM ammonium acetate W 45z acetonitrile. The transition 798.3 to 651.1 was monitored. Quinidine was separated with a Capcellpak TM MGII column using isocratic elution with 55z 0.1z-formic acid W 45z methanol, with monitoring of the 325.0 to 307.2 transition.
Results and Discussion
Nakayama et al. reported the absorption proˆle of vinblastine from rat intestinal loops. 15) They found that vinblastine was absorbed in the duodenum and ileum, but not at all in jejunum. Therefore, weˆrst examined the absorption ratio in various intestinal segments of mice. 
15)
To examine the reason for the segment-dependent absorption of vinblastine in mouse intestine, real-time PCR was used to assess the relative abundance of mRNAs of various eOEux transporters and cyp3a11 in the epithelial layer of small intestine and liver (Fig. 1 ). There were clear diŠerences in the levels of expression of mdr1a mRNA between intestinal segments in wild-type mice, i.e. colonÀileumÀrectumÀjejunumÀduoden-um, and this is in accordance with human data reported by various researchers. [16] [17] [18] However, the diŠerences of mdr1a mRNA expression could not account for the variation of the absorption ratio of vinblastine in diŠerent intestinal regions. A possible explanation might be segment-related diŠerences in the permeability of vinblastine, as discussed below. No signiˆcant diŠerences in the expression of multidrug resistanceassociated protein 2 (mrp2), breast cancer resistance protein (bcrp) and cyp3a11 mRNAs were observed between mdr1a W 1b ＋ W ＋ and mdr1a W 1b -W -mice. Thus, mdr1a W 1b -W -mice did not functionally compensate for mdr1a W 1b gene-deˆciency with enhanced synthesis of mRNAs for mrp2, bcrp and cyp3a11.
It is important to know what kinds of substrates are likely to show P-gp-dependent intestinal absorption. Although several researchers have concluded that the eŠect of P-gp on intestinal absorption of drugs can not be predicted from in vitro data, 5, 19) we investigated the feasibility of using a simple assay with Caco-2 cells to classify P-gp substrates. Figure 2 shows the intestinal permeability of several P-gp substrates and two standard compounds, mannitol and antipyrine. Horizontal and vertical axes in Fig. 2 represented in‰ux permeability (apical-to-basolateral: P app,in‰ux ) and the ratio of eOEux to in‰ux permeability (basolateral-to-apical W apical-to-basolateral: Papp,eOEux W Papp,in‰ux) of compounds, respectively. For all the substrates examined, except vinblastine, colchicines and fexofenadine, in‰ux permeability was higher than 1×10 -6 cm W sec. For P-gp substrates except vinblastine, the values of the B-to-A W A-to-B ratio were relatively low, i.e., below 8. On the other hand, the eOEux W in‰ux permeability ratio of vinblastine was quite high, at 12.1. Thus, there seem to be at least two classes of P-gp substrates. The intestinal absorption proˆle of some substrates, such as verapamil, was not aŠected by P-gp, whereas that of others such as vinblastine was aŠected by P-gp. The vinblastine-type substrates have high a‹nity for P-gp, as judged from the value of the eOEux W in‰ux ratio in Caco-2 cells. Moreover, they may be easily captured by P-gp in intestinal epithelial cells before transport to the basolateral side, since they show low permeability. Consequently, the absorption proˆle of vinblastine-type substrates is quite poor, and such P-gp substrates with low absorption and high P-gp a‹nity would be unfavorable for development as oral drugs. Therefore, we suggest that our Caco-2 assay represents a useful screening method.
After oral administration of [ 3 H]verapamil (1 mg W kg), the plasma concentration of total radioactivity reached Cmax of 73.5±9.6 mg W mL at 8 hr in mdr1a W 1b ＋ W ＋ mice and 67.8±9.6 mg W mL at 8 hr in mdr1a W 1b -W -mice. The AUC0-24hr, an index of absorbability, were not signiˆcantly diŠerent between the strains, i.e., 1479±105 and 1409±92 mg･hr W mL for mdr1a W 1b ＋ W ＋ and mdr1a W 1b -W -mice, respectively (Fig. 3, Table 2 ). In the case of [ 3 H]vinblastine, the Cmax values in mdr1a W 1b ＋ W ＋ and mdr1a W 1b -W -mice were 117±27 and 170± 32 ng W mL at 8 hr after oral administration, respectively. The AUC0-24hr of [ 3 H]vinblastine was 3714±318 ng･hr W mL for mdr1a W 1b -W -mice, 1.5 times greater than that for wild-type mice, as shown in Fig. 4 and Table 2 . Thus, the pharmacokinetic proˆle of vinblastine was aŠected by P-gp, while that of verapamil was not. This diŠerence of pharmacokinetic proˆles between verapamil and vinblastine is considered to be due to the diŠerence of intestinal absorption characteristics between them. Therefore, pharmacokinetic proˆling using mdr1a W 1b ＋ W ＋ and mdr1a W 1b -W -mice represents another possible screening method to conˆrm whether a compound is a vinblastine-type substrate or not.
We also examined the plasma concentration of radioactivity after oral administration of [ 3 H]-vinblastine to male rats. The PK proˆle showed puzzling twin peaks of plasma concentration, i.e., theˆrst Cmax was 33.5 ng W mL at 0.5 hr, and this was followed by a higher peak of 66.5 ng W mL at 8 hr after administration, as shown in Fig. 5 . We have encountered a series of P-gp substrates, which exhibit vinblastine-type low permeability of less than 1×10 -6 cm W sec, and high a‹nity for P-gp (ratio of more than 10 in our Caco-2 assay). Despite the apparently desirable physicochemical parameters (solubility, metabolic stability and permeability through artiˆcial membranes) of these compounds, they showed poor bioavailability and vinblastine-like twin peaks in the PK proˆles after oral administration to rats. Their bioavailability increased slightly with increasing dose, and the twin peaks disappeared upon oral co-administration of these compounds with verapamil or cyclosporine as P-gp substrates W inhibitors (data not shown).
In conclusion, there appear to be at least two types of P-gp substrates in terms of intestinal absorption characteristics, i.e., verapamil-type and vinblastinetype, and these could be diŠerentiated with our Caco-2 system. Vinblastine-type substrates may be absorbed in the duodenum and ileum, but not the jejunum, and show twin Cmax peaks and quite low bioavailability after oral dosing in rats. In general, hepatic metabolism of drugs by CYPs and enzymatic conjugation of drugs are called Phase I and Phase II elimination processes, respectively. Recently, primary active excretion into bile (positive removal of xenobiotics from the body) has been designated as Phase III elimination. 20, 21) We suggest that intestinal carrier-mediated eOEux may be regarded as a Phase 0 clearance system for removal of xenobiotics from the body.
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